Trial · NCT04516291
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 80
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Placebo | -1.1 | Standard Error 2.76 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 80 mg Q4W | -23.5 | Standard Error 4.08 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 60 mg Q2W | -23.2 | Standard Error 4.02 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 120 mg Q4W | -25.3 | Standard Error 4.23 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 80 mg Q2W | -28.8 | Standard Error 3.02 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 160 mg Q4W | -27.8 | Standard Error 2.88 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 120 mg Q2W | -25.8 | Standard Error 2.84 | Percent change | |
| Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | Vupanorsen: 160 mg Q2W | -27.6 | Standard Error 3.57 | Percent change | |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Placebo | TG | -2.53 | Standard Deviation 31.247 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 80 mg Q4W | TG | -42.17 | Standard Deviation 28.081 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 60 mg Q2W | TG | -44.71 | Standard Deviation 22.725 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 120 mg Q4W | TG | -39.57 | Standard Deviation 32.546 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 80 mg Q2W | TG | -49.21 | Standard Deviation 21.049 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 160 mg Q4W | TG | -40.33 | Standard Deviation 21.311 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 120 mg Q2W | TG | -50.55 | Standard Deviation 20.234 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 160 mg Q2W | TG | -55.76 | Standard Deviation 14.625 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Placebo | ApoB | 0.66 | Standard Deviation 20.372 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 80 mg Q4W | ApoB | -12.12 | Standard Deviation 15.839 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 60 mg Q2W | ApoB | -12.30 | Standard Deviation 12.604 | Percent change |
| Percent Change From Baseline in Triglyceride (TG), Apolipoprotein B (ApoB), Low-Density Lipoprotein-Cholesterol (LDL-C), and Non-HDL-C at Week 16 | Vupanorsen: 120 mg Q4W | ApoB | -10.41 | Standard Deviation 17.067 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04516291/results